Effects on Sleep Quality and Bioelectrical Parameters of Cellular Health After Administration of a Plant Protein Supplement Combined With Ashwagandha and Rhodiola
| Registry | NCT07461402, acronym TECOS |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: quadruple, treatment |
| Enrollment | 100 (Actual) |
| Sponsor | Universidad Pablo de Olavide (Other); collaborators: Universidad Europea de Madrid |
| Conditions | Sleep Quality, Sleep Disorders, Insomnia |
| Interventions | Plant Protein Supplement, Rhodiola rosea Extract, Ashwagandha KSM-66, Placebo (Dietary supplement) |
| Dates | start 2025-11-01, primary completion 2025-12-02, completion 2025-12-04, first posted 2026-03-10, last updated 2026-03-10 |
| Locations | 1 site in Spain |
Related Papers Related Patents Related Grants Related Experts
All trials for Sleep Quality All trials for Sleep Disorders All trials of Plant Protein Supplement All trials of Rhodiola rosea Extract
This study evaluates whether a combination of plant protein with adaptogenic herbs (ashwagandha and rhodiola) can improve sleep quality in middle-aged adults with sleep disturbances.
One hundred participants aged 35-70 years with sleep problems will be randomly assigned to receive either the active intervention or placebo for 30 days. The active group will receive 27 grams per day of plant protein (pea, rice, and hemp isolate) combined with 300 mg of Rhodiola rosea and 500 mg of Withania somnifera (ashwagandha KSM-66®) in tablet form. The placebo group will receive maltodextrin and placebo capsules that look identical.
Sleep quality will be measured daily using a validated Sleep Quality Questionnaire (SQQ) that assesses difficulty falling asleep, daytime sleepiness, and overall sleep quality. Body composition and cellular health will also be measured using bioimpedance analysis at the beginning and end of the study.
The primary hypothesis is that the combination of plant protein with ashwagandha and rhodiola will produce greater improvements in sleep quality compared to placebo. The study will also evaluate the safety and tolerability of this nutritional intervention.
BACKGROUND AND RATIONALE
Sleep disturbances affect 30-40% of the adult population worldwide and are associated with serious health consequences including insulin resistance, weight gain, and increased cardiovascular risk. While pharmaceutical sleep medications (benzodiazepines and hypnotics) are commonly prescribed, they have significant limitations including potential for addiction, adverse side effects, and disruption of natural sleep architecture.
Natural alternatives are increasingly sought. Protein supplementation may influence sleep through multiple mechanisms: proteins provide tryptophan (a precursor to serotonin and melatonin), help stabilize nocturnal blood glucose levels, and can generate bioactive peptides with sedative properties. However, studies on protein and sleep have shown mixed results.
Adaptogens are medicinal plants that help the body adapt to stress. Ashwagandha (Withania somnifera) has been extensively studied and shown to improve sleep quality, reduce sleep latency, and decrease nighttime awakenings, likely through modulation of the hypothalamic-pituitary-adrenal (HPA) axis and GABAergic effects. Rhodiola rosea, another well-characterized adaptogen, has demonstrated stress-resilience enhancement and neuroprotective effects.
This study is the first to investigate the combined effects of plant protein with both ashwagandha and rhodiola on sleep quality, hypothesizing a synergistic multimodal effect.
STUDY DESIGN
This is a randomized, double-blind, placebo-controlled, parallel-group clinical trial conducted at three sites in Spain (Pozoblanco, Seville, and Yecla). The study was approved by the Research Ethics Committee of the Virgen Macarena and Virgen del Rocío University Hospitals (Code: 2061-N-21) on June 21, 2021, and is conducted in accordance with the Declaration of Helsinki.
PARTICIPANTS
One hundred adults aged 35-70 years with sleep disturbances will be recruited and randomized 1:1 to intervention (VERUM, n=50) or placebo (PLACEBO, n=50) groups. Key inclusion criteria include experiencing sleep disturbances, willingness to consume the plant protein supplement, and ability to provide informed consent. Exclusion criteria include known allergies to study ingredients, current use of sleep medications, serious medical conditions, and pregnancy or lactation.
INTERVENTION
VERUM Group: Participants will receive plant protein powder (27 g/day containing pea, rice, and hemp protein isolate) plus two tablets daily containing Rhodiola rosea (300 mg) and Withania somnifera KSM-66® (500 mg) for 30 consecutive days.
PLACEBO Group: Participants will receive maltodextrin powder (matched for appearance and taste) plus placebo capsules (identical in appearance) for 30 consecutive days.
All participants and investigators will be blinded to group assignment throughout the study period.
OUTCOME MEASURES
Primary Outcome: Sleep quality will be assessed using the validated Sleep Quality Questionnaire (SQQ), completed daily by participants. The SQQ evaluates three domains:
* Sleep Difficulty subscale (range 0-16)
* Daytime Sleepiness subscale (range 0-24)
* Total Sleep Score (range 0-40)
Higher scores indicate worse sleep quality.
Secondary Outcome: Phase angle, a bioelectrical parameter reflecting cellular health and membrane integrity, will be measured using bioimpedance analysis (BIA-TELELAB) at baseline (Day 0) and end of intervention (Day 30).
STATISTICAL ANALYSIS
Sleep quality data will be analyzed using longitudinal mixed models to account for repeated daily measurements. Phase angle will be analyzed using non-parametric tests. Effect sizes will be calculated using Cohen's d. The significance level will be set at α = 0.05. Analysis will include all participants who complete outcome assessments.
PROPOSED MECHANISMS
The proposed mechanisms of action include: (1) tryptophan provision for serotonin/melatonin synthesis, (2) HPA axis modulation and cortisol reduction, (3) GABAergic effects, (4) nocturnal glycemic stabilization, and (5) enhanced stress resilience through adaptogenic pathways.
SAMPLE SIZE JUSTIFICATION
A sample size of 100 participants (50 per group) was determined to provide adequate statistical power to detect clinically meaningful differences in sleep quality measures between groups, accounting for an estimated dropout rate of 20-30%.
SAFETY MONITORING
Participants will be monitored for adverse events throughout the study. Any adverse events will be recorded and reported according to institutional and regulatory requirements.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| VERUM: Plant Protein + Ashwagandha + Rhodiola | Experimental | Dietary Supplement: Plant Protein Supplement; Dietary Supplement: Rhodiola rosea Extract; Dietary Supplement: Ashwagandha KSM-66 | Participants will receive the active intervention for 30 consecutive days: (1) Plant Protein Powder containing 27 grams daily of pea, rice, and hemp protein isolates, mixed with water or beverage, consumed once daily; (2) Rhodiola rosea extract tablets containing 300 milligrams daily; (3) Withania somnifera (Ashwagandha) KSM-66® tablets containing 500 milligrams daily. Tablets are taken with meals. The protein provides tryptophan for neurotransmitter synthesis. Adaptogens modulate stress response via hypothalamic-pituitary-adrenal (HPA) axis and have gamma-aminobutyric acid (GABA) receptor effects. All products administered under double-blind conditions. |
| PLACEBO: Maltodextrin + Placebo Capsules | Placebo comparator | Dietary Supplement: Placebo | Participants will receive placebo products for 30 consecutive days: (1) Placebo Powder containing maltodextrin, matched to active protein powder in appearance, taste, texture, color, and packaging, mixed with water or beverage, consumed once daily; (2) Placebo Capsules containing inert excipients, identical in appearance, size, color, shape, and packaging to active adaptogen tablets, taken with meals. No active ingredients. All products administered under double-blind conditions. Participants, care providers, investigators, and outcomes assessors are blinded to treatment assignment. Placebo products are indistinguishable from active products. |
Sex: All, ages: 35 Years to 70 Years
Inclusion Criteria: * Adults aged 35 to 70 years (inclusive) * Experiencing sleep disturbances or sleep quality problems * Willing and able to consume plant protein supplement daily for 30 days * Willing and able to take adaptogen tablets daily for 30 days * Able to provide written informed consent * Able to complete daily sleep quality questionnaires * Available for baseline and follow-up assessments * Willing to maintain regular lifestyle habits during the study period Exclusion Criteria: * Age less than 35 years or greater than 70 years * Known allergies or hypersensitivity to any study ingredients (pea protein, rice protein, hemp protein, Rhodiola rosea, Withania somnifera/ashwagandha, or excipients) * Current use of prescription sleep medications or hypnotics * Current use of other herbal supplements for sleep (washout period may be allowed) * Serious or unstable medical conditions that could interfere with study participation or safety * Severe psychiatric disorders requiring medication * Uncontrolled metabolic diseases (for example, uncontrolled diabetes, thyroid disorders) * Pregnancy or lactation * Planning to become pregnant during the study period * Participation in another clinical trial within the past 30 days * Inability to understand or comply with study procedures * Shift workers or individuals with irregular sleep schedules * Recent major life events significantly affecting sleep patterns
| Facility | City | Country | Status |
|---|---|---|---|
| Farmacia Molina | Seville, Cordoba | Spain |